Therapeutic Leaps To Help Families Thrive
Why Higher Medicine?
We are passionate & ready to bring cures to patients in the fields so close to the goal line.
We see a chance for the next biomedical revolution where others may miss.
We serve higher purposes as each one of us define it, from financial prosperity to human flourishing.
Investing in the future of medical research starting with Friedreich's Ataxia.
Friedreich’s ataxia affects multiple tissues in patients, but lacks an effective treatment addressing all symptoms
%20(1).gif)
.gif)
Cook A, Giunti P. Br Med Bull 2017, 124(1):19-30
1. Iron-Sulfur Cluster Biogenesis 2. Reactive Oxygen Species
p38 inhibitor can break the maladaptive feedback loop that depresses ISCB1, the primary biochemical defect in FA
p38 inhibitor treatment showed promising efficacy in human FA cells and animal model, and may reverse 31P MRS biomarker in patients
p38 inhibitors are well-characterized in other indications and available for in-licensing to leapfrog into a Phase 2 study in FA
Novel Penn ferroptosis inhibitors for the follow-on program are secured
Cotticelli et al., J Pharmacol Exp Ther 369:47–54, 2019; Cotticelli et al., ACS Chem. Neurosci. 2020, 11, 2535−2542
Additionally, investment in the epigenetic platform now can lead to the next biomedical revolution for many cures
Malachowski et al., Cell 2023 186, 5840–5858.e1–e21
Higher Medicine offers the de-risked and synergetic portfolio
FA clinical development & commercial paths were well established, creating clear value inflection & exit opportunities for investors
High step-up potential in a wide range of indications sharing the same mechanisms
Higher Medicine is led by a team of seasoned pharmaceutical executives and advised by Dr. Wilson and his colleagues who helped pioneer the first & only approved FA drug
Agile and capital-efficient support structure is in place
HM is raising $2M and poised for strategic investors looking to achieve rapid value inflection paired with high upside in the long-run
News
Company Announcements
April 25, 2025
Higher Medicine Secures $500,000 Seed Investment from Desire Ventures
Higher Medicine seed investment secured from Desire Ventures